📝 SummarXiv

Abstract

The FDA conducted a benefit-risk assessment for Moderna's COVID vaccine mRNA-1273 prior to its full approval, announced 1/31/2022. The FDA focused its assessment on males of ages 18-64 years because the agency's risk analysis was limited to vaccine-attributable myocarditis/pericarditis (VAM/P) given the excess risk among males. The FDA analysis concluded that vaccine benefits clearly outweighed risks, even for 18-25-year-old males (those at highest VAM/P risk). We reanalyze the FDA benefit-risk assessment using information available through the third week of January 2022 and focusing on 18-25-year-old males. We use the FDA's framework but extend its model by accounting for protection derived from prior COVID infection, finer age-stratification in COVID-hospitalization rates, and incidental hospitalizations (those of patients who test positive for COVID but are being treated for something else). We also use more realistic projections of Omicron-infection rates and more accurate rates of VAM/P. With hospitalizations as the principal endpoint of the analysis (those prevented by vaccination vs. those caused by VAM/P), our model finds vaccine risks outweighed benefits for 18-25-year-old males, except in scenarios projecting implausibly high Omicron-infection prevalence. Our assessment suggests that mRNA-1273 vaccination of 18-25-year-old males generated between 16% and 63% more hospitalizations from vaccine-attributable myocarditis/pericarditis alone compared to COVID hospitalizations prevented (over a 5-month period of vaccine protection assumed by the FDA). The preceding assessment is based on assumptions drawn from data available before 1/22/22. Moreover, these assumptions are validated by subsequently available data. Thus, we show that the outcome of a benefit-risk assessment for vaccination may be dramatically impacted by accounting for the benefits derived from prior infection